Myocardial cell membrane stress ionic dyskinesia reversal by diltiazem
1São Francisco de Assis Cardiovascular Foundation, Belo Horizonte, Minas Gerais, Brazil.
Insights
Diltiazem, a calcium channel blocker, effectively normalized exercise stress test results in patients with silent myocardial ischemia. This suggests calcium-dependent myocardial contraction plays a role in silent ST segment depression.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Exercise stress testing can induce silent myocardial ischemia.
- Myocardial stress dyskinesia is a potential cause of this ischemia.
- Calcium channel blockers may offer a therapeutic approach.
Purpose of the Study:
- To investigate the efficacy of diltiazem in patients with exercise stress testing-induced silent myocardial ischemia.
- To explore the role of calcium-dependent myocardial contraction in silent ST segment depression.
Main Methods:
- A study involving 25 patients with positive ergometric testing but no obstructive coronary artery disease.
- Patients received diltiazem (90 mg three times daily) and underwent repeat treadmill electrocardiography exercise testing.
- Key parameters analyzed included ST segment depression, heart rate, and exercise performance.
Main Results:
- Diltiazem abolished atypical precordial pain in all patients.
- ST segment depression (both J and Y points) was significantly reduced post-treatment (P<0.001).
- Functional cardiac classification improved significantly (P<0.01) with diltiazem treatment.
Conclusions:
- Diltiazem effectively prevented exercise-induced silent ST segment depression in patients without obstructive coronary artery disease.
- These findings support the involvement of calcium-dependent myocardial contraction dyskinesia in the genesis of silent ST segment depression.
Abstract:
Based on previous observations of cardioplegic ionic myocardial distress, myocardial stress dyskinesia was investigated as another possible cause of exercise stress testing-induced silent myocardial ischemia by analyzing the efficacy of the myocytic calcium channel blocker diltiazem in normalizing the results of patients who previously tested positive.From October 2004 to February 2006, 25 patients (13 women [52%]; aged between 28 and 71 years; mean age 56.9 years) complaining of precordial pain, with no coronary artery obstruction detected by scintigraphy and coronary cineangiography studies, presenting with positive ergometric testing, defined by ST segment depression, with no precordial pain or arrhythmia during testing, were treated with diltiazem in three daily doses of 90 mg, and were restudied five or seven days after the first examination. Treadmill electrocardiography exercise testing was performed using the standard Bruce protocol, analyzing the following parameters: the J point and Y point of the ST segment depression, maximum oxygen uptake reached, heart rate, double product and exercise performance measured in metabolic equivalents.The administration of diltiazem abolished patients' complaints of atypical precordial pain in all cases and blocked ST segment depression, both J point (control: mean 2.3+/-0.5 mm; with treatment: 0.4+/-0.5 mm; P<0.001) and Y point (control: mean 1.9+/-0.7 mm; with treatment: 0.1+/-0.3 mm; P<0.001). The heart rate variations were not significant (P>0.05), with mean values of 156.2+/-12.0 beats/min for the control and 149.0+/-19.2 beats/min with treatment. There was significant (P<0.01) improvement in the functional classification of the heart with treatment (mean 2.7+/-0.9 for the control and 2.0+/-0.7 with treatment), without significant variations (P>0.05) in maximum oxygen uptake and double product results.The administration of the myocytic calcium channel blocker diltiazem impeded the occurrence of the silent ST segment depression, previously induced by exercise stress testing in patients without confirmed obstructive coronary artery disease, supporting the involvement of calcium-dependent myocardial contraction ionic dyskinesia in the genesis of silent ST segment depression.
More Related Videos
10:01High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
Published on: March 31, 2022
09:36Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
Related Concept Videos
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Cardiomyopathy II: Dilated Cardiomyopathy
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: Inotropic Agents
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
